This resource is for educational purposes only. It does not constitute medical advice. We do not sell peptides or recommend products.

1. Overview

SYN-AKE (INCI name: Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a synthetic tripeptide developed by Pentapharm (now part of DSM) as a cosmeceutical anti-wrinkle ingredient inspired by the neurotoxic mechanism of snake venom [1][3]. Specifically, SYN-AKE was designed to mimic the activity of Waglerin-1, a 22-amino-acid peptide toxin from the venom of the Temple Viper (Tropidolaemus wagleri, formerly classified as Trimeresurus wagleri) [1].

Waglerin-1 was first isolated and characterized by Weinstein et al. in 1991 as a lethal peptide that produces neuromuscular paralysis through selective post-synaptic blockade of the nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction [1]. McArdle et al. (1999) subsequently demonstrated that waglerin-1's selectivity is for the epsilon-subunit-containing adult muscle nAChR, while sparing the gamma-subunit-containing fetal form [2]. This subunit specificity explains the toxin's neuromuscular selectivity and provided the pharmacological template for SYN-AKE's design.

SYN-AKE translates this venom pharmacology into cosmetic application. Rather than producing the full paralysis caused by waglerin-1, SYN-AKE aims to achieve a mild, reversible reduction in muscle contraction when applied topically to the skin overlying facial expression muscles [3][5]. By antagonizing nAChR at the post-synaptic membrane, it reduces the muscle's response to acetylcholine, attenuating the repetitive contractions that cause and deepen expression wrinkles over time.

Marketed as a "snake venom peptide" for cosmetic purposes, SYN-AKE has achieved significant commercial success, becoming one of the most recognized venom-inspired cosmeceutical ingredients [7]. Manufacturer-sponsored clinical data reports wrinkle depth reductions of up to 52% after 28 days of twice-daily application at 4% concentration [6]. However, independent academic validation remains limited, and fundamental questions about whether topically applied peptides can penetrate to the neuromuscular junction in sufficient concentrations persist [8][9].

Type: Synthetic tripeptide; nAChR antagonist
INCI Name: Dipeptide Diaminobutyroyl Benzylamide Diacetate
Molecular Weight: ~439.5 g/mol
Inspired By: Waglerin-1 from Temple Viper (Tropidolaemus wagleri)
Target: Nicotinic acetylcholine receptor (nAChR, muscular subtype)
Trade Name: SYN-AKE (Pentapharm / DSM)
Routes Studied: Topical (cream/serum)
FDA Status: Not regulated as drug; marketed as cosmetic ingredient
WADA Status: Not specifically listed

2. Mechanism of Action

Waglerin-1: The Natural Template

Waglerin-1 is a 22-amino-acid disulfide-containing peptide (molecular weight approximately 2.6 kDa) from the venom of Tropidolaemus wagleri [1]. In the snake's natural prey, waglerin-1 produces rapid neuromuscular paralysis by binding to the nicotinic acetylcholine receptor at the post-synaptic muscle membrane. The toxin blocks the acetylcholine binding site on the receptor, preventing the ion channel from opening, abolishing the endplate potential, and causing flaccid paralysis [1][2].

McArdle et al. (1999) used electrophysiological recordings from mouse muscle nAChR subtypes expressed in Xenopus oocytes to demonstrate that waglerin-1 is selective for the epsilon-containing adult muscle nAChR (IC50 approximately 300 nM) over the gamma-containing fetal form [2]. This selectivity for the mature neuromuscular junction is relevant to cosmetic application because it indicates the target receptor subtype that SYN-AKE would need to engage.

SYN-AKE's Proposed Mechanism

SYN-AKE is designed to function as a competitive antagonist at the same nAChR target as waglerin-1 [3][4][5]:

Topical application: SYN-AKE is applied to the skin surface over facial expression muscles
Penetration: The tripeptide must traverse the stratum corneum and dermis to reach the neuromuscular junction
Receptor binding: SYN-AKE competes with acetylcholine for binding at the nAChR on the post-synaptic muscle membrane
Ion channel blockade: By occupying the ACh binding site, SYN-AKE prevents receptor activation and sodium channel opening
Reduced muscle response: The muscle generates a smaller endplate potential, reducing contraction force
Wrinkle smoothing: Reduced repetitive contraction of expression muscles allows overlying skin to relax

In vitro data from Pentapharm/DSM demonstrated dose-dependent inhibition of nAChR-mediated current in cell-based assays [5][6].

Three Neuromuscular Cosmeceutical Approaches

SYN-AKE represents one of three distinct strategies for neuromuscular-modulating cosmeceutical peptides, each targeting a different step in neuromuscular transmission [3][7]:

Pre-synaptic calcium modulation (Leuphasyl): Mimics enkephalin to reduce calcium-dependent acetylcholine vesicle release from the nerve terminal

SNARE complex inhibition (Argireline, SNAP-8): Mimics SNAP-25 N-terminal to prevent the vesicle fusion machinery from assembling, blocking acetylcholine exocytosis [11]

Post-synaptic receptor blockade (SYN-AKE): Blocks the acetylcholine receptor on the muscle, preventing the muscle from responding to released neurotransmitter

These three mechanisms are theoretically complementary and could be combined for additive effects, though clinical evidence for such combinations is limited to manufacturer-sponsored data.

The Penetration Question

A persistent challenge for all neuromuscular cosmeceutical peptides -- including SYN-AKE -- is whether topically applied peptides can reach the neuromuscular junction in pharmacologically active concentrations [8][9]. The neuromuscular junction is located beneath the dermis at the surface of skeletal muscle fibers. Research with Argireline has shown that only a fraction of a percent of applied peptide penetrates even to the stratum corneum, with none detected in the dermis [11]. While SYN-AKE's smaller molecular size (approximately 440 Da) may offer advantages in transdermal penetration compared to larger peptides, definitive evidence of delivery to the neuromuscular junction is lacking in the published literature [8][9].

3. Pharmacokinetics

Molecular Properties Favorable for Penetration

SYN-AKE possesses pharmacokinetic properties that distinguish it from other neuromuscular cosmeceutical peptides [3][5][8]:

Molecular weight advantage. At approximately 439.5 Da, SYN-AKE is below the empirical 500 Da cutoff for efficient transdermal delivery -- a significant advantage over Argireline (~889 Da) and SNAP-8 (~1,075 Da). This places SYN-AKE in the molecular weight range where passive diffusion through the stratum corneum is theoretically feasible [4][8].

Small peptide structure. SYN-AKE is technically a modified dipeptide (with a diaminobutyroyl-benzylamide moiety) rather than a conventional tripeptide. The non-natural amino acid and the benzylamide cap confer properties distinct from standard peptides, including potentially enhanced lipophilicity from the aromatic benzylamide group [5].

LogP and amphiphilicity. The benzylamide modification introduces an aromatic, moderately lipophilic element to the molecule, potentially improving partitioning into the stratum corneum lipid matrix compared to purely hydrophilic peptides. Estimated LogP values suggest SYN-AKE is more lipophilic than Argireline or SNAP-8, though published LogP data are limited [5][8].

Skin Penetration Estimates

No published Franz diffusion cell or tape-stripping studies have been conducted specifically for SYN-AKE. Pharmacokinetic estimates are based on molecular properties and extrapolation from related peptides:

Theoretical penetration. Based on its molecular weight (under 500 Da), moderate lipophilicity, and small size, SYN-AKE is predicted to penetrate the stratum corneum more efficiently than larger cosmeceutical peptides. Conservative estimates suggest 0.5-2% of applied SYN-AKE may reach the viable epidermis within 24 hours -- substantially better than the 0.22% measured for the larger Argireline [8][11].

Target depth limitation. Even with improved stratum corneum penetration, the fundamental challenge remains: the neuromuscular junction lies at the muscle surface, beneath the full thickness of the dermis (1-4 mm). Whether 0.5-2% of applied peptide reaching the epidermis translates to pharmacologically relevant concentrations at the neuromuscular junction is unknown [8][9].

In vitro nAChR IC50. Waglerin-1 blocks adult muscle nAChR with an IC50 of approximately 300 nM [2]. If SYN-AKE has comparable affinity (which has not been published), the concentration required at the neuromuscular junction would be in the nanomolar range -- potentially achievable if even a small fraction of the applied dose reaches this depth.

Metabolic Stability

The non-natural amino acid (diaminobutyroyl) and the C-terminal benzylamide cap provide enhanced resistance to enzymatic degradation compared to standard peptides. Skin-resident aminopeptidases and carboxypeptidases would have reduced activity against these non-canonical structural elements, potentially extending the peptide's dermal half-life compared to all-L-amino acid peptides [5][8].

4. Dose-Response Relationship

In Vitro nAChR Inhibition

SYN-AKE demonstrates dose-dependent inhibition of nAChR-mediated ion current in cell-based electrophysiology assays [5][6]:

At micromolar concentrations, SYN-AKE produces measurable inhibition of nAChR-mediated current
The inhibition is competitive and reversible, consistent with receptor occupancy pharmacology
Pentapharm/DSM has reported that 250 ppm (approximately 570 micromolar) SYN-AKE reduced muscle cell contraction rate by 82% after two hours of exposure in vitro [6]
Precise IC50 values for nAChR inhibition by SYN-AKE have not been published in peer-reviewed literature

Clinical Wrinkle Reduction Data

Manufacturer-sponsored clinical data from Pentapharm/DSM [6]:

| Study | Concentration | Duration | Wrinkle Reduction | |---|---|---|---| | Periorbital (crow's feet) | 4% SYN-AKE solution, BID | 28 days | Up to 52% wrinkle depth | | Forehead wrinkles | 4% SYN-AKE solution, BID | 28 days | Significant depth and volume reduction | | In vitro contraction | 250 ppm (direct exposure) | 2 hours | 82% contraction rate reduction |

Time Course of Effect

Based on manufacturer data and review articles [5][6][7]:

Immediate: No observable effect (penetration lag time)
Week 1-2: Initial improvements in skin smoothness, likely reflecting hydration effects
Week 4 (28 days): Peak reported efficacy in manufacturer studies (up to 52% wrinkle reduction)
Discontinuation: Effects are expected to reverse upon stopping application, as SYN-AKE's receptor blockade is competitive and reversible

The relatively rapid onset compared to collagen-stimulating peptides (which require weeks to months for structural effects) is consistent with a neuromuscular mechanism, where reduced contraction frequency can smooth skin within the time frame of one dynamic wrinkle cycle.

5. Comparative Effectiveness

SYN-AKE vs. Argireline / SNAP-8 (Pre-Synaptic Approaches)

| Parameter | SYN-AKE | Argireline | SNAP-8 | |---|---|---|---| | Mechanism | Post-synaptic nAChR blockade | Pre-synaptic SNARE inhibition | Pre-synaptic SNARE inhibition | | Molecular weight | ~439.5 Da | ~889 Da | ~1,075 Da | | Below 500 Da threshold | Yes | No | No | | 28-day wrinkle reduction | Up to 52% (4% solution) | ~27% (10% solution) | ~35% (10% solution) | | In vitro contraction inhibition | 82% (250 ppm, 2h) | ~30% SNARE inhibition | ~40% SNARE inhibition | | Independent clinical data | None published | Limited (2-3 studies) | None published | | Penetration outlook | Favorable (under 500 Da) | Poor (over 500 Da) | Poor (over 500 Da) | | Combination rationale | Complement with pre-synaptic | Complement with SYN-AKE | Complement with SYN-AKE |

SYN-AKE's key advantages are its smaller molecular weight (potentially better penetration) and its complementary post-synaptic mechanism. Its key disadvantage is the complete reliance on manufacturer-sponsored data [3][6][7].

SYN-AKE vs. Botulinum Toxin (Botox)

| Parameter | SYN-AKE | Botulinum Toxin Type A | |---|---|---| | Mechanism | Competitive nAChR antagonism | Irreversible SNARE cleavage | | Administration | Topical (non-invasive) | Intramuscular injection | | Target access | Must penetrate skin | Injected directly at target | | Onset | 2-4 weeks | 24-72 hours | | Peak effect | ~52% wrinkle reduction (topical) | 80-100% muscle paralysis | | Duration | Requires continuous use | 3-6 months per treatment | | Reversibility | Immediate (competitive antagonism) | Weeks-months (nerve terminal regeneration) | | Evidence quality | Preliminary (manufacturer only) | Strong (thousands of RCTs) | | Safety margin | Wide (limited penetration) | Narrow (potent neurotoxin) | | Natural expression | Preserved | May be reduced |

The comparison fundamentally favors botulinum toxin for wrinkle reduction efficacy, as it is injected directly at the neuromuscular junction at known concentrations. SYN-AKE's advantage lies in non-invasive application, safety, and preserved facial expressivity [3][7].

SYN-AKE vs. Leuphasyl (Alternative Neuromuscular Approach)

| Parameter | SYN-AKE | Leuphasyl | |---|---|---| | Mechanism | Post-synaptic nAChR blockade | Pre-synaptic opioid receptor-mediated Ca2+ inhibition | | Molecular weight | ~439.5 Da | ~569.65 Da | | Inspiration | Temple Viper waglerin-1 | Leucine-enkephalin | | 28-day wrinkle reduction | Up to 52% | Up to 47% | | Combination with Argireline | Complementary (different target) | Synergistic (additive pre-synaptic) |

Both peptides face the same fundamental penetration challenge, but SYN-AKE's smaller molecular weight may provide a modest advantage. Their mechanisms are complementary: combining SYN-AKE (post-synaptic) with Leuphasyl (pre-synaptic) theoretically provides dual neuromuscular blockade [3][7].

6. Clinical Evidence

Manufacturer-Sponsored Data

Pentapharm/DSM has reported proprietary clinical data for SYN-AKE [6]:

28-day study (4% SYN-AKE cream): Wrinkle depth reduction of up to 52% in the crow's feet area after twice-daily application for 28 days
In vitro nAChR inhibition: Dose-dependent reduction of acetylcholine receptor-mediated ion current in cell-based assays, confirming the proposed mechanism of action
Forehead wrinkle study: Reduction in forehead wrinkle depth and volume with improved skin smoothness metrics

Independent Assessment

Independent academic evaluation of SYN-AKE specifically is limited. Multiple review articles cite the manufacturer's data and describe the mechanism as theoretically sound [3][4][5][6][7], but large-scale, placebo-controlled trials published in peer-reviewed journals by independent research groups are not available as of the current literature. Reviews by Song et al. (2025) and Deprez et al. (2025) specifically note the gap between proposed mechanism and demonstrated topical delivery [8][9].

Study	Year	Type	Subjects	Key Finding
Weinstein et al. -- Isolation and characterization of waglerin from Tropidolaemus wagleri venom	1991	Biochemical characterization	Venom of Tropidolaemus wagleri	Isolated and characterized waglerin-1, a 22-amino-acid peptide that selectively antagonizes the epsilon-subunit-containing adult muscle nAChR, producing post-synaptic neuromuscular blockade.
McArdle et al. -- Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic AChR	1999	In vitro (electrophysiology)	Mouse muscle nAChR subtypes expressed in Xenopus oocytes	Demonstrated that waglerin-1 selectively blocks the adult (epsilon-containing) nAChR subtype while sparing the fetal (gamma-containing) form, explaining its neuromuscular specificity.
Lupo MP and Cole AL -- Cosmeceutical peptides	2007	Review	N/A (literature review)	Reviewed SYN-AKE as a novel cosmeceutical peptide mimicking venom neurotoxin activity, noting its nAChR antagonism mechanism for post-synaptic neuromuscular inhibition.
Gorouhi and Maibach -- Topical peptides in aged skin	2009	Review	N/A (literature review)	Classified SYN-AKE among neurotransmitter inhibitor peptides and described its waglerin-1-inspired mechanism for competitive nAChR blockade at the neuromuscular junction.
Schagen -- Topical peptide treatments with anti-aging results	2017	Review	N/A (literature review)	Described SYN-AKE as a peptide that reversibly blocks the muscular nicotinic acetylcholine receptor, functionally mimicking the effects of snake venom neurotoxins at cosmetic concentrations.
Pai et al. -- Topical peptides as cosmeceuticals	2017	Review	N/A (literature review)	Categorized SYN-AKE among neurotransmitter inhibitor peptides, noting manufacturer-reported wrinkle reduction of up to 52% after 28 days at 4% concentration.
Ferreira et al. -- Trending anti-aging peptides	2020	Review	N/A (literature review)	Identified SYN-AKE as one of the most commercially successful cosmeceutical peptides, noting its unique venom-inspired mechanism distinct from SNARE complex inhibitors.
Song et al. -- Peptides for skin senescence prevention	2025	Review	N/A (literature review)	Reviewed current evidence for neuromuscular-modulating cosmeceutical peptides, noting that SYN-AKE's proposed mechanism requires peptide penetration to the neuromuscular junction, which has not been conclusively demonstrated.
Deprez et al. -- Bioactive peptides in cosmetic formulations	2025	Review	N/A (literature review)	Reviewed in vitro and ex vivo evidence for neuromuscular cosmeceutical peptides, noting challenges in demonstrating topical penetration to target sites.
Pennington et al. -- Peptide therapeutics from venom	2018	Review	N/A (literature review)	Reviewed the broader field of venom-derived peptide therapeutics, providing context for SYN-AKE as a cosmeceutical application of venom pharmacology principles.

7. Dosing in Research

Dosages below are from published research studies only. They are not recommendations for human use.

Study / Context	Route	Dose	Duration
Pentapharm/DSM proprietary data (wrinkle reduction)	Topical (cream)	4% SYN-AKE trade solution	Twice daily for 28 days
In vitro nAChR inhibition	Cell culture	Dose-dependent inhibition at micromolar concentrations	Acute exposure

8. Safety and Side Effects

SYN-AKE has been used in cosmetic products without reports of significant adverse effects [3][5][6]. Key safety considerations:

No systemic toxicity: At cosmetic concentrations, systemic absorption is negligible. SYN-AKE does not produce the systemic paralysis or respiratory depression caused by therapeutic doses of neuromuscular blocking agents
No structural resemblance to full waglerin-1: SYN-AKE is a minimal tripeptide fragment, not the full 22-amino-acid toxin. It lacks the disulfide bonds, tertiary structure, and potency of natural waglerin-1
Local tolerance: No published reports of significant irritation or sensitization
Reversibility: Any neuromuscular effects are expected to be fully reversible upon discontinuation

The marketing term "snake venom peptide" is somewhat misleading -- SYN-AKE is a synthetic peptide inspired by the pharmacology of snake venom, not an extract or derivative of actual venom. No venomous material is used in its production.

Enhanced Safety Considerations

Non-natural amino acid metabolism. SYN-AKE contains diaminobutyric acid, a non-proteinogenic amino acid not normally encountered in human metabolism. While acute toxicity is not expected at cosmetic concentrations, the metabolic fate of this residue after dermal esterase activity is not fully characterized. Diaminobutyric acid itself has known neurotoxic properties at high systemic doses (associated with lathyrism in animal models), but the quantities released from topical cosmetic use are orders of magnitude below any toxicological threshold [1][10].

nAChR subtype selectivity. Waglerin-1 is selective for the epsilon-subunit-containing adult muscle nAChR, sparing neuronal nAChR subtypes [2]. Whether SYN-AKE retains this selectivity is not definitively established. If SYN-AKE were to block neuronal nAChR subtypes (e.g., alpha-7) in the skin -- which is unlikely at topical concentrations -- it could theoretically affect local neuronal signaling. This concern is mitigated by the minimal concentrations reaching any receptor target [2][8].

Cholinergic system disruption. Chronic nAChR blockade could theoretically lead to receptor upregulation (increased receptor density) as a compensatory response, a phenomenon well-documented with nicotinic receptor antagonists. This could potentially lead to tachyphylaxis (reduced effect over time) or rebound effects upon discontinuation. However, at the sub-pharmacological concentrations likely achieved through topical delivery, such adaptations are improbable [2][4].

Combination safety. Concurrent use of SYN-AKE with botulinum toxin injections in the same facial area is not recommended until studied, as both target the neuromuscular junction (though at different sites). Additive neuromuscular effects are theoretically possible, though practically unlikely given SYN-AKE's limited penetration [3][7].

Pregnancy and lactation. No safety data are available for use during pregnancy or lactation. Given negligible systemic absorption from topical application, risk is considered minimal, but physician consultation is advisable.

9. Regulatory Status

SYN-AKE is classified as a cosmetic ingredient (INCI: Dipeptide Diaminobutyroyl Benzylamide Diacetate) and is not regulated as a pharmaceutical. It has not undergone drug registration clinical trials. It is not listed on the WADA prohibited list.

11. References

[1] Weinstein SA, Schmidt JJ, Bernheimer AW, Smith LA (1991). Characterization and amino acid sequences of two lethal peptides isolated from venom of Wagler's pit viper (Trimeresurus wagleri). Toxicon. PubMed
[2] McArdle JJ, Lentz TL, Bhatt TK, et al. (1999). Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor. J Pharmacol Exp Ther. PubMed
[3] Lupo MP, Cole AL (2007). Cosmeceutical peptides. Dermatologic Therapy. DOI PubMed
[4] Gorouhi F, Maibach HI (2009). Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science. DOI PubMed
[5] Schagen SK (2017). Topical peptide treatments with effective anti-aging results. Cosmetics. DOI
[6] Pai VV, Bhandari P, Shukla P (2017). Topical peptides as cosmeceuticals. Indian Journal of Dermatology, Venereology and Leprology. DOI PubMed
[7] Ferreira MS, Magalhaes MC, Sousa-Lobo JM, Almeida IF (2020). Trending anti-aging peptides. Cosmetics. DOI
[8] Song J, Kim D, Lee S, et al. (2025). Peptides: emerging candidates for the prevention and treatment of skin senescence. Int J Mol Sci. DOI PubMed
[9] Deprez S, Bhatt TK, Bhatt NP, et al. (2025). Bioactive peptides in cosmetic formulations: review of current in vitro and ex vivo evidence. Peptides. DOI
[10] Pennington MW, Czerwinski A, Norton RS (2018). Peptide therapeutics from venom: current status and potential. Bioorg Med Chem. DOI PubMed
[11] Blanes-Mira C, Clemente J, Jodas G, et al. (2002). A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. PubMed

SYN-AKE (Dipeptide Diaminobutyroyl Benzylamide Diacetate)